Enhancement of Meditation Analgesia by Opioid Antagonist in Experienced Meditators.
Enhancement of Meditation Analgesia by Opioid Antagonist in Experienced Meditators.
复制标题
阿片类拮抗剂增强经验丰富的冥想者的冥想镇痛作用。
DOI：
10.1097/psy.0000000000000580
复制
发表时间：
2018
影响因子：
3.3
通讯作者：
Berkman,ElliotT
中科院分区：
文献类型：
--
作者：
May,LisaM;Kosek,Peter;Zeidan,Fadel;Berkman,ElliotT
研究一直表明，长期冥想练习与减轻疼痛有关，但长期冥想练习减轻疼痛的神经机制仍不清楚。本研究测试了内源性阿片参与与长期冥想practice. MethodsElectricalpain的冥想镇痛与阿片拮抗剂纳洛酮的随机，双盲，交叉管理（0.15-mg/kg推注剂量，然后0.2-mg/kg每小时输注剂量）与32名健康，经验丰富的冥想练习者和标准化开放监测冥想。冥想期间疼痛评分（疼痛强度：6.41±1.32;疼痛不愉快：3.98±2.17）显著低于基线时（疼痛强度：6.86±1.04，t（31）= 2.476，p=.疼痛不适：4.96±1.75，t（31）= 3.746，p=. 001，Cohen的d= 0.68），证实了冥想镇痛的存在。比较生理盐水和纳洛酮显示疼痛强度显著降低（t（31）= 3.12，p=.疼痛不适（t（31）= 3.47，p=. 002，d= 0.62），纳洛酮组（疼痛强度：5.53±1.54;疼痛不愉快：2.95±1.88）较生理盐水组（疼痛强度：6.41±1.32;疼痛不愉快：3.98±2.17）显著降低。纳洛酮不仅未能消除冥想镇痛，但也使冥想镇痛strength.ConclusionsLong-term meditation practice不依赖于内源性阿片类药物，以减少疼痛。纳洛酮对阿片受体的阻断增强了冥想镇痛;在冥想期间，纳洛酮的疼痛评分显著低于生理盐水。纳洛酮诱导的阿片受体阻滞剂增强冥想镇痛可能的生物学机制进行了讨论。
ObjectiveStudies have consistently shown that long-term meditation practice is associated with reduced pain, but the neural mechanisms by which long-term meditation practice reduces pain remain unclear. This study tested endogenous opioid involvement in meditation analgesia associated with long-term meditation practice.MethodsElectrical pain was induced with randomized, double-blind, cross-over administration of the opioid antagonist naloxone (0.15-mg/kg bolus dose, then 0.2-mg/kg per hour infusion dose) with 32 healthy, experienced meditation practitioners and a standardized open monitoring meditation.ResultsUnder saline, pain ratings were significantly lower during meditation (pain intensity: 6.41±1.32; pain unpleasantness: 3.98±2.17) than at baseline (pain intensity: 6.86±1.04, t (31)= 2.476, p=. 019, Cohen's d= 0.46; pain unpleasantness: 4.96±1.75, t (31)= 3.746, p=. 001, Cohen's d= 0.68), confirming the presence of meditation analgesia. Comparing saline and naloxone revealed significantly lower pain intensity (t (31)= 3.12, p=. 004, d= 0.56), and pain unpleasantness (t (31)= 3.47, p=. 002, d= 0.62), during meditation under naloxone (pain intensity: 5.53±1.54; pain unpleasantness: 2.95±1.88) than under saline (pain intensity: 6.41±1.32; pain unpleasantness: 3.98±2.17). Naloxone not only failed to eliminate meditation analgesia but also made meditation analgesia stronger.ConclusionsLong-term meditation practice does not rely on endogenous opioids to reduce pain. Naloxone's blockade of opioid receptors enhanced meditation analgesia; pain ratings during meditation were significantly lower under naloxone than under saline. Possible biological mechanisms by which naloxone-induced opioid receptor blockade enhances meditation analgesia are discussed.